| Gender Preference | None |
| Age Group | 18 - 99 years |
| Research Start Date | October 25, 2012 |
| Research End Date | March 1, 2015 |
| Principal Investigator | Mohammed Milhem, MD |
| Description | A Randomized Phase II Trial of Carboplatin, Paclitaxel, Bevacizumab, with or without Everolimus for Therapy of Metastatic Malignant Melanoma
Participants in this research study have been diagnosed with Stage IV malignant melanoma (melanoma that has spread to other parts of the body) which cannot be removed with surgery. The purpose of this study is to find out what effects (good and bad) the combination of the study drugs (Carboplatin, paclitaxel, bevacizumab and everolimus) has on the participant and the melanoma. Approximately 7 people will take part in this study conducted by Investigators at the University of Iowa. Participation in the study will continue until cancer becomes worse or participant or Doctor decide to end the treatment. |
| Contact Info | Clarine Halvorsen 319-356-3944 |
| Keywords | span itemProp='description'>cancer ; IRB#201208719 ; melanoma ; Milhem ; Phase 2 ; Phase II ; |